We therefore examined the efficacy and cellular mechanism of action of fadraciclib in a small panel of breast cancer cell lines, including two human TNBC cell lines (Cal51 and MDA-MB-468) and the HER2-amplified HCC1954 breast cancer cell line. Here, ERBB2 is linked to breast carcinoma.